What mediates the benefits associated with dipeptidyl peptidase-IV inhibition?

Diabetologia

Department of Medicine, Lund University, Lund, Sweden.

Published: April 2005

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00125-005-1706-6DOI Listing

Publication Analysis

Top Keywords

mediates benefits
4
benefits associated
4
associated dipeptidyl
4
dipeptidyl peptidase-iv
4
peptidase-iv inhibition?
4
mediates
1
associated
1
dipeptidyl
1
peptidase-iv
1
inhibition?
1

Similar Publications

Regulatory effects of resveratrol on nitric oxide signaling in cardiovascular diseases.

Pharmacol Rep

January 2025

Center for Global Health Research, Saveetha Medical College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India.

Cardiovascular illnesses are multifactorial disorders and represent the primary reasons for death worldwide, according to the World Health Organization. As a signaling molecule, nitric oxide (NO) is extremely permeable across cellular membranes owing to its unique molecular features, like its small molecular size, lipophilicity, and free radical properties. Some of the biological effects of NO are vasodilation, inhibition in the growth of vascular smooth muscle cells, and functional regulation of cardiac cells.

View Article and Find Full Text PDF

The role of heparin in sepsis therapy has been widely debated. The controversy surrounding heparin's use as an anticoagulant in sepsis may stem from differences in sepsis definitions, study designs, timing and dosage of drug administration, treatment duration, complications, and patient severity. In this study, we aimed to determine the optimal timing and dosage of heparin in patients with sepsis, identify specific subgroups that could benefit from heparin therapy, and explore laboratory markers to assess its efficacy.

View Article and Find Full Text PDF

Background: The combination therapy of the B-Raf proto-oncogene (BRAF) inhibitor dabrafenib and the mitogen-activated protein kinase kinase (MEK) inhibitor Trametinib has shown favorable outcomes in patients initially identified with BRAF mutations. However, there are currently no large-scale study data focusing on the use of a triple therapy regimen of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) plus dabrafenib and trametinib in patients with newly concomitant BRAF mutations after acquiring resistance to EGFR-TKIs. Our study aimed to explore the efficacy and safety of the triple therapy regimen through a multi-center real-world experience.

View Article and Find Full Text PDF

Airway inflammation, a hallmark feature of asthma, drives many canonical features of the disease, including airflow limitation, mucus plugging, airway remodeling, and hyperresponsiveness. The T2 inflammatory paradigm is firmly established as the dominant mechanism of asthma pathogenesis, largely due to the success of inhaled corticosteroids and biologic therapies targeting components of the T2 pathway, including IL-4, IL-5, IL-13, and thymic stromal lymphopoietin (TSLP). However, up to 30% of patients may lack signatures of meaningful T2 inflammation (ie, T2 low).

View Article and Find Full Text PDF

Strong, affiliative bonds often function to facilitate social competition through cooperative defence of resources, but the benefits of social bonds may be low when direct competition is less intense or less beneficial. In such cases, one possible outcome is that relationships are weak and undifferentiated. Alternatively, negotiating stable, selectively tolerant relationships may be a strategy to mitigate the costs and risks of sharing space when direct competition is undesirable.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!